A positive HPV 16, 18/45 test means your cervical screening detected one or more of the human papillomavirus types most strongly linked to cervical cancer. These three types are singled out by name on test reports because they carry a higher risk of progressing to precancerous or cancerous changes than the other dozen or so high-risk HPV types your body might encounter. But “higher risk” is not the same as a cancer diagnosis, and most people who test positive for these types will never develop cancer. What follows from the result depends on several factors, and understanding them can take a lot of the fear out of the process.
Why These Three Types Get Their Own Line on the Report
There are at least 14 HPV types classified as high-risk, but HPV 16, 18, and 45 sit at the top of the danger list. HPV 16 is the single most common type found in cervical cancers worldwide, and HPV 18 is the second most common. HPV 45 trails behind them but consistently ranks third or fourth depending on the population studied. Their dominance in cancer cases is the reason most FDA-approved screening tests call them out individually rather than lumping them in with the rest.1PubMed Central. Need for expanded HPV genotyping for cervical screening
The numbers make the distinction concrete. In a large U.S. screening study, women positive for HPV 16 had roughly a 14–15% chance of harboring a high-grade precancer (CIN3 or worse), depending on age group. HPV 18 carried a risk ranging from about 3% in younger women to 9% in those 30 and older. Other high-risk types clustered in the low single digits.2PubMed. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial A separate analysis of women with normal Pap results found that those positive for HPV 16 had about a 7% risk of CIN3 or higher, compared with roughly 2.6% for HPV 18, about 1.1% for HPV 45, and around 2.2% for all other high-risk types combined.3American Journal of Clinical Pathology. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology: Data From the Baseline Phase of the Onclarity Trial HPV 16 clearly leads the pack, HPV 18 and 45 occupy a middle tier, and everything else falls lower.
What Happens After the Result
Current U.S. guidelines use a risk-based framework. When your estimated immediate risk of having a CIN3-level precancer reaches about 4% or higher, the recommendation is a colposcopy, a close-up examination of your cervix with a magnifying instrument and, usually, a small biopsy.4PubMed Central. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors Because HPV 16 and 18 carry risks that frequently clear that threshold on their own, a positive genotype result for either type generally triggers a colposcopy referral even when your Pap cytology looks normal. For HPV 45 and other high-risk types with normal cytology, additional triage steps such as a repeat test in one year may be offered instead, since the immediate risk tends to fall closer to or just below the 4% line.
If your Pap also shows abnormal cells, the urgency goes up. Women with borderline or mildly abnormal Pap results who tested positive for HPV 16 had a two-year risk of high-grade precancer exceeding 30%.5JNCI: Journal of the National Cancer Institute. Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities And among people with atypical glandular cells on cytology and an HPV 16/18/45 genotype, the odds of adenocarcinoma or its precursor were dramatically elevated compared to those with other high-risk types and normal cytology.6PubMed Central. The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma The pairing of genotype and cytology together is what drives the clinical decision, not either result alone.
When only cytology is normal but HPV 16 or 18 is detected, colposcopy biopsy still finds high-grade lesions at meaningful rates. In one study, about 48% of women with HPV 16 or 18 and normal-appearing cells on Pap had high-grade lesions on biopsy, compared to roughly 16% of women positive for other high-risk types.7PubMed Central. Comparison of Colposcopic Biopsy Results of Patients Who have Cytomorphological Normal but HPV 16-18 or Other High-Risk HPV Subtypes Positive This is exactly why guidelines do not let a reassuring Pap override a positive HPV 16/18 genotype.
A Special Connection to Adenocarcinoma
Most cervical cancers are squamous cell carcinomas, which arise from the flat cells lining the outer cervix. A smaller but growing share are adenocarcinomas, which develop from the glandular cells deeper inside the cervical canal. HPV 18 and 45 have a particularly strong association with adenocarcinoma. In a large Chinese study, HPV 18 was found in about 41% of cervical adenocarcinomas versus only 8% of squamous cell cancers. HPV 45 showed a similar tilt, appearing in roughly 4% of adenocarcinomas compared to about 1% of squamous tumors. HPV 16 dominated both types but was more concentrated in squamous cancers.8Journal of Lower Genital Tract Disease. The Variable Characteristics of Human Papillomavirus in Squamous Cell Carcinoma and Adenocarcinoma of Cervix in China
This matters because adenocarcinomas are harder to catch on a Pap smear. They develop higher up in the cervical canal where sampling is less reliable. Genotyping for HPV 18 and 45 helps flag women who may be at higher risk of a cancer type that standard cytology is more likely to miss.
Most Infections Clear on Their Own
A positive test does not mean the virus is there to stay. The immune system clears the majority of HPV infections, including these high-risk types, within a couple of years. In a study of young women aged 18 to 25, roughly 69% of HPV 16 infections cleared within two years and about 82% cleared within four years. HPV 18 cleared even faster: around 85% by two years and 90% by four years.9PubMed Central. Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18–25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT) Another longitudinal study in Ethiopia looking at all high-risk types found that about 74% of infections cleared within six months and 87% by two years, though HPV 16 was among the types most likely to persist.10PubMed Central. High-Risk HPV Persistence and Clearance Patterns Among Women in Ethiopia: A Longitudinal Study
Persistence is the real concern. In a Dutch cohort of young women, about 58% of HPV 16 infections persisted over follow-up, compared with 44% of HPV 18 infections.11PubMed. Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young women These numbers differ from the Costa Rica trial partly because of how persistence was defined and how long women were followed, but the pattern is consistent: HPV 16 is stickier than HPV 18, and persistent infections are the ones that can progress. It is the infections that do not clear after a year or two that your clinician is watching for.
How These Viruses Cause Trouble
HPV 16, 18, and 45 are not just “present” when cancer develops. They actively drive the process. These viruses produce two proteins, called E6 and E7, that disable two of the cell’s most important tumor-suppressing safeguards. E6 promotes the destruction of a protein called p53, which normally stops damaged cells from multiplying. E7 disrupts a different control protein that keeps cell division in check. With both brakes disabled, infected cells can accumulate genetic damage and keep dividing anyway.12Cancer Science. Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins HPV 16 and 18 produce especially potent versions of these proteins, which is a core reason they outpace other high-risk types in causing cancer.
The virus also evades your immune system more effectively than you might expect. It infects only the surface layer of epithelial cells, which limits how much the immune system “sees” it. The virus’s lifecycle is designed to keep a low profile, triggering less inflammation and fewer immune alarm signals than many other infections.13PubMed Central. Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System This stealthy behavior helps explain why some infections linger long enough to cause precancerous changes.
The Role of the Vaginal Microbiome
Whether an HPV infection clears or persists is not entirely up to the virus and your immune system. The bacterial community in the vagina plays a role. A healthy vaginal microbiome dominated by certain Lactobacillus species, particularly one called Lactobacillus crispatus, is associated with a lower likelihood of HPV persistence and progression. Conversely, a disrupted bacterial community with higher levels of bacteria such as Gardnerella and Sneathia is associated with persistent high-risk HPV infection and progression to high-grade lesions.14PubMed Central. The vaginal microbiome in HPV persistence and cervical cancer progression One study found that certain bacterial species, including Prevotella bivia and Anaerococcus prevotii, were more abundant in women whose HPV infections persisted compared with those whose infections cleared, and that the abundance of A. prevotii was higher in women co-infected with HPV 16 and 18 specifically.15Scientific Reports. Changes in the vaginal microbiome in female patients with condyloma acuminatum and its impact on persistent HPV infection
This area of research is still developing, and there are no clinical recommendations yet to test or modify the vaginal microbiome as part of HPV management. But it helps explain why two people with the same HPV type can have very different outcomes.
Newer Triage Tools
If you test positive for one of the other 12 high-risk HPV types (not 16, 18, or 45), your clinician may use an additional test to decide whether you need colposcopy or can safely wait. One increasingly common approach is a dual-stain test that looks for two proteins, p16 and Ki-67, in cervical cells. When both proteins appear simultaneously in the same cell, it suggests the virus is actively disrupting the cell cycle. A large sub-study found this dual-stain approach was substantially more sensitive than a standard Pap for sorting out which HPV-positive women truly needed further evaluation. Combining automatic colposcopy referral for HPV 16/18-positive women with dual-stain triage for other high-risk types yielded the highest sensitivity for detecting serious precancers.16PubMed. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial
Current guidelines still recommend colposcopy for all HPV 16/18-positive individuals regardless of dual-stain results, because even when the stain is negative, the underlying risk remains above comfortable thresholds. The dual stain is more useful as a gatekeeper for the “other 12” group, where it can spare many women an unnecessary procedure.17PubMed Central. p16/ki‐67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions
Age and HPV Type Distribution
HPV 16 is disproportionately common in younger women who develop precancers. In a study tracking cervical precancer cases across age groups, HPV 16 was responsible for about 68% of high-grade lesions among women aged 18 to 26 but only about 28% among women 56 and older. As HPV 16’s share dropped with age, other high-risk types filled the gap.18PubMed Central. HPV types by age in cervical cancer precursors: predominance of HPV 16 in young women This does not mean older women with HPV 16 are at lower risk. Rather, it means that the precancers clinicians find in older women are more likely to be caused by a diverse mix of HPV types. For screening, the implication is that genotyping becomes somewhat less decisive as a triage tool in older age groups, because non-16/18 types carry a larger share of the disease burden.
A related question older women sometimes have is whether a newly detected HPV infection represents a brand-new exposure or a dormant virus waking up. Research on women aged 55 to 85 found that most newly detected HPV infections in this age group appeared to be genuinely new acquisitions rather than reactivation of an old latent infection, based on the pattern of antibody responses before and after detection.19PubMed Central. Human papillomavirus in older women: new infection or reactivation? The practical lesson: an HPV-positive result later in life does not necessarily mean you have been silently harboring the virus for decades.
The Emotional Side of the Result
Few screening tests carry as much emotional baggage as an HPV result. Because HPV is sexually transmitted, a positive test can trigger feelings of shame, anxiety, and worry about relationships that are completely out of proportion to the medical risk. Qualitative research has found that women who tested positive for HPV reported feeling stigmatized, stressed about disclosure to partners, and fearful about cancer, even when their overall clinical picture was reassuring.20PubMed Central. Social and psychological impact of HPV testing in cervical screening: a qualitative study A more recent cross-sectional study confirmed that women with positive HPV results reported higher levels of anxiety, depression, and psychosocial burden, including negative impacts on their sexual lives, compared to those with negative results.21PubMed Central. Impact of HPV test results and emotional responses on psychosocial burden among Taiwanese women: a cross-sectional study
Some context that often gets lost: HPV is extraordinarily common. Most sexually active adults will acquire at least one HPV infection at some point. A positive test says something about the virus’s biology, not about your behavior or character. If the emotional weight of the result is affecting your wellbeing or your relationships, that is worth bringing up with your clinician or a counselor.
What About Your Partner?
A common reaction to a positive HPV 16/18 result is worry about transmitting the virus to a partner or figuring out “who gave it to whom.” There is no routine HPV test approved for men outside of research settings, and the CDC advises against routine HPV testing in male partners because there are no standardized reliable methods and no established management pathways for HPV-positive men.22PubMed Central. The challenging approach to the management of male partners of HPV-positive women Testing is sometimes considered in specific circumstances, such as for HIV-positive men who have sex with men, but for most male partners, there is simply nothing actionable to do with a result.
Vaccination is a different story. Gender-neutral HPV vaccination programs, where boys and men are vaccinated alongside girls and women, reduce transmission in both directions and lower the burden of HPV-related cancers for everyone.23PubMed Central. Breaking barriers: why including boys and men is key to HPV prevention If your partner has not been vaccinated and is still within the recommended age range, that conversation is worth having.
Vaccination After a Positive Test
People often wonder whether getting vaccinated after already testing positive offers any benefit. The HPV vaccine is highly effective at preventing new infections with the types it covers, and real-world data show major declines in HPV 16 and 18 infections among vaccinated populations along with herd protection for unvaccinated individuals.24PubMed Central. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer However, vaccination does not help clear an infection you already have. A study evaluating women who were HPV 16/18-positive at the time of vaccination found no evidence that the vaccine accelerated clearance or reduced progression to precancerous lesions.25American Journal of Obstetrics and Gynecology. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
That does not mean vaccination is pointless if you already have one type. The vaccine covers multiple types, and being infected with HPV 16 does not protect you against HPV 18 or the other types in the vaccine. Your clinician can help you decide whether vaccination still makes sense based on your age and history.
HPV 16 and 18 Beyond the Cervix
Cervical screening is where most people first encounter the phrase “HPV 16/18,” but these types are also the dominant cause of anal squamous cell carcinoma, where HPV is considered a necessary cause of the disease.26PubMed Central. Prevalence of HPV in anal cancer: exploring the role of infection and inflammation HPV 16 in particular plays a major role in oropharyngeal cancers (cancers of the base of the tongue and tonsils), vulvar cancer, vaginal cancer, and penile cancer. A positive cervical result does not tell you anything about infection at other anatomical sites, but it is a reminder that these types have a broad reach.
Racial Differences in HPV Type Patterns
HPV type distribution is not uniform across racial and ethnic groups, and this has practical implications for how well genotype-based screening performs. In U.S. screening data, Black women were less likely to test positive for HPV 16 but more likely to carry other high-risk types compared to White women.27PubMed Central. Racial Differences in Human Papillomavirus Type 16 Prevalence in Women with Atypical Squamous Cells of Undetermined Significance of the Uterine Cervix A study of precancers and cancers by race found that a higher proportion of high-grade precancers in Black women were caused by HPV types not covered by the current 9-valent vaccine, with HPV 35 being notably more prevalent.28JNCI: Journal of the National Cancer Institute. Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management
Adding a layer of complexity, when HPV 16 is present in Hispanic and Black women, its DNA is more likely to be found in a fully integrated state, a form associated with greater cancer-driving potential. This could partly explain the higher rates of abnormal cytology and cervical dysplasia observed in these groups even when the prevalence of HPV 16 infection is lower.29PubMed Central. Racial/ethnic differences in HPV 16/18 genotypes and integration status among women with a history of cytological abnormalities These findings are part of a broader conversation about whether screening algorithms built primarily on HPV 16/18 genotyping perform equally well across populations, or whether expanded genotyping panels would better serve certain groups.
How Reliable Is the Test Itself?
Most HPV screening in the U.S. and Europe uses one of a handful of commercially available assays. A large head-to-head comparison of six HPV tests found high agreement among the major DNA-based platforms, with overall positivity rates for high-risk HPV running between about 13% and 16% across the screening population. For HPV 16 specifically, positivity ranged from roughly 2.8% to 3.5% across DNA-based tests, while HPV 18 rates ranged from about 0.9% to 1.4%. Tests based on detecting viral RNA rather than DNA tended to have somewhat lower positivity rates, which may reflect that they pick up only actively replicating virus.30British Journal of Cancer. Comparing the performance of six human papillomavirus tests in a screening population The practical takeaway is that the major tests agree well on who is HPV 16/18-positive, so a positive result on any FDA-approved test should be taken at face value.